Novadiscovery
prospectively predicted the LDL-C outcomes of Merck's Phase 3 CORALreef Lipids trial using its jinkō causal-AI in-silico clinical trial platform, announced in November 2025 — a virtual patient "twin" simulating real-world physiology, disease progression and therapeutic response ahead of the trial's actual readout.
- Country
- France
Prospectively validated
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Patient digital twins & in-silico trials | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.